ChatGPT short summary:
The study is a prospective observational cohort study of 197 cancer patients who were prescribed off-label ivermectin plus mebendazole, with 122 completing a six-month follow-up. Among those 122 patients, 48.4% reported either no current evidence of disease or tumor regression, another 36.1% reported stable disease, and 15.6% reported progression, producing a reported “clinical benefit ratio” of 84.4%. About 25% reported side effects, which were generally described as mild and mostly gastrointestinal. However, the crucial limitation is that the cancer outcomes were self-reported and were not independently confirmed by imaging or medical records, there was no control group, and many patients were simultaneously receiving chemotherapy, radiation, surgery, supplements, dietary interventions, or other treatments. The authors themselves therefore characterize the findings as hypothesis-generating rather than proof that ivermectin and mebendazole caused the cancer improvements, and call for randomized controlled trials.